Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Geron to Participate at Upcoming Investor Conferences in April


Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:

A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of the Company's website under Events. An archive of the webcast will be available on the Company's website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat for the treatment of transfusion dependent anemia in patients with lower-risk myelodysplastic syndromes (TD LR-MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. In addition, an MAA is under review in the European Union for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (R/R MF). To learn more, visit www.geron.com or follow us on LinkedIn.


These press releases may also interest you

at 17:45
The global automotive battery testers market  size is estimated to grow by USD 78.9 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 3.73%  during the forecast period.  Increasing lifespan of...

at 17:44
Non-cash impairment of SEK 11.4 billion to be recorded in the second quarter 2024, relating to the impairment of intangibles mainly attributed to the Vonage acquisitionReflects lower anticipated market growth in some of Vonage's current portfolioThe...

at 17:40
Bayen Group, a leading provider of IT solutions and services, has been nominated for the prestigious Southern California Minority Supplier Development Council (SCMSDC) Supplier of the Year award by Northrop Grumman, a global aerospace and defense...

at 17:25
The global secondary tickets market size is estimated to grow by USD 132.1 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 34.25% during the forecast period. Rising popularity of sports events is driving...

at 17:25
The global electric car rental market size is estimated to grow by USD 18.00 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 16.68% during the forecast period. Increasing demand for rental cars due...

at 17:20
The global supercomputer market size is estimated to grow by USD 33.45 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 28.54% during the forecast period. Commercial customers increasingly adopting...



News published on and distributed by: